Inspire Veterinary Partners, Inc. Class A (IVP) AI Stock Analysis

• Market Cap: $5.90M
• Dividend Yield: N/A
• Average Volume (3M): 135.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: -10.70%
• EPS Growth: 99.69%
• Country: US
• Employees: 113
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Personal Products & Services
• EPS (TTM): -0.50
• Shares Outstanding: 3,609,285
• 10 Day Avg. Volume: 58,517
• 30 Day Avg. Volume: 135,727
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 4.66
• Enterprise Value/Revenue: 1.80
• Enterprise Value/Gross Profit: 7.39
• Enterprise Value/Ebitda: -3.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: $1.00 ▲(13.64% Upside)

Inspire Veterinary Partners, Inc. is facing significant financial difficulties, with declining revenues and high leverage being the most critical issues. Technical analysis also indicates bearish trends, and the valuation metrics suggest the stock is overvalued given its negative earnings. These factors contribute to a low overall stock score.

Inspire Veterinary Partners, Inc. Class A Business Overview & Revenue Model

Company Description

Inspire Veterinary Partners, Inc. owns and operates veterinary hospitals in the United States. The company specializes in small animal general practice hospitals, which serve companion pets, canine, and feline breeds. Its hospitals provide preventive care for companion animals consisting of annual health exams and parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; and skin and coat health, and other breed specific preventive care services. The company also provides surgical services, which include soft tissue procedures, such as spays and neuters, mass removals, splenectomies, gastropexies, orthopedic procedures, and other surgical offerings; and care and alternative procedures, such as acupuncture, chiropractic, and other health and wellness services. Inspire Veterinary Partners, Inc. was incorporated in 2020 and is based in Virginia Beach, Virginia.

How the Company Makes Money

Inspire Veterinary Partners generates revenue primarily through a combination of service fees from partnered veterinary practices and a percentage of the profits from these practices. The company charges management fees for its operational support services, which may include marketing, financial management, and staff training. Additionally, IVP benefits from revenue sharing agreements, where it receives a portion of the profits from the veterinary clinics it partners with. Significant partnerships with pharmaceutical and pet care companies also contribute to its earnings through collaborative marketing efforts and supply chain agreements, allowing IVP to enhance its service offerings and streamline costs.

Inspire Veterinary Partners, Inc. Class A Financial Statement Overview

Summary

Inspire Veterinary Partners, Inc. faces significant financial challenges with declining revenues, high leverage, and negative profitability margins. Despite some improvement in free cash flow, the overall financial health remains weak, with potential risks due to high debt levels and negative equity.

Income Statement

Inspire Veterinary Partners, Inc. shows a concerning trend in its income statement. The company has experienced a significant revenue decline of 69.4% in the TTM period, with negative net profit margins consistently above -80%. The gross profit margin has also decreased from 41.3% in 2024 to 24.3% in the TTM. These figures indicate challenges in maintaining profitability and revenue growth.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 31.88 in the TTM, indicating significant reliance on debt financing. The return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is low, suggesting potential financial instability.

Cash Flow

Cash flow analysis shows improvement in free cash flow growth at 12.08% in the TTM, but operating cash flow remains negative. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses. However, the negative operating cash flow to net income ratio highlights ongoing operational challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.29M	16.59M	16.68M	9.83M	2.55M	0.00
Gross Profit	3.72M	6.86M	3.55M	2.55M	829.29K	0.00
EBITDA	-9.16M	-9.50M	-10.84M	-2.91M	-977.46K	0.00
Net Income	-12.91M	-14.26M	-14.79M	-4.91M	-1.33M	-5.52K
Balance Sheet
Total Assets	20.81M	20.20M	21.79M	20.19M	6.33M	21.97K
Cash, Cash Equivalents and Short-Term Investments	158.94K	523.69K	178.96K	444.25K	2.06M	21.97K
Total Debt	14.23M	16.37M	18.42M	23.61M	6.69M	0.00
Total Liabilities	20.36M	18.63M	22.58M	25.32M	7.20M	0.00
Stockholders Equity	446.26K	1.56M	-788.26K	-5.14M	-869.09K	21.97K
Cash Flow
Free Cash Flow	-9.32M	-10.24M	-4.20M	-2.84M	-2.32M	-5.52K
Operating Cash Flow	-9.26M	-10.01M	-3.82M	-2.66M	-1.01M	-5.52K
Investing Cash Flow	-1.94M	-238.00K	-1.87M	-14.67M	-4.02M	0.00
Financing Cash Flow	11.39M	10.59M	5.63M	15.71M	7.07M	269.16K

Inspire Veterinary Partners, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVP, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 0.96, below the 50-day MA of 0.94, and below the 200-day MA of 1.53, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.21 is Neutral, neither overbought nor oversold. The STOCH value of 28.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVP.

Inspire Veterinary Partners, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRM	―	$19.20M	13.81	48.22%	―	13.71%	―
Sector *	―	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
XWEL	―	$5.63M	-0.26	-1069.01%	―	-6.93%	22.70%
EJH	―	$20.16M	―	―	―	-11.14%	98.81%
IVP	―	$5.90M	-0.07	-809.91%	―	-10.70%	99.69%

Inspire Veterinary Partners, Inc. Class A Corporate Events

Inspire Veterinary Partners Expands Funding with New Investors

On September 9, 2025, Inspire Veterinary Partners, Inc. amended its securities purchase agreement to include new institutional investors for the issuance and sale of Series B convertible preferred stock and related warrants. This amendment resulted in an additional closing with 1,253 shares sold, generating approximately $1.0 million in gross proceeds, and was executed under exemptions from public offering registration, targeting accredited investors.

The most recent analyst rating on (IVP) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.

Inspire Veterinary Partners Regains Nasdaq Compliance

Inspire Veterinary Partners, Inc. announced on September 2, 2025, that it has regained compliance with Nasdaq’s Stockholders’ Equity Requirement after previously being notified on April 10, 2025, about non-compliance. The company received confirmation of compliance from Nasdaq on August 26, 2025, based on its Form 8-K filed with the SEC on August 20, 2025.

The most recent analyst rating on (IVP) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.

Inspire Veterinary Partners Raises $5M for Nasdaq Compliance

Inspire Veterinary Partners, Inc. faced a compliance issue with Nasdaq’s minimum stockholders’ equity requirement, as disclosed on April 10, 2025. The company submitted a compliance plan on May 23, 2025, and subsequently entered into a Securities Purchase Agreement on July 28, 2025, to issue Series B convertible preferred stock and warrants, raising approximately $5 million in the first closing on July 29, 2025. This move is believed to have brought the company back into compliance with Nasdaq’s requirements, although Nasdaq will continue to monitor the situation to ensure ongoing compliance.

The most recent analyst rating on (IVP) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.

Inspire Veterinary Partners Secures $5M in Series B Funding

On July 28, 2025, Inspire Veterinary Partners, Inc. entered into a Securities Purchase Agreement with accredited investors to issue up to 7,590 shares of Series B convertible preferred stock and accompanying warrants, potentially raising up to $10 million. The first closing on July 29, 2025, resulted in $5 million in proceeds. The company plans to use the funds for working capital, acquisitions of veterinary practices, and to address Nasdaq deficiencies. This move aligns with Inspire’s growth strategy and aims to enhance its market positioning by expanding its healthcare services.